MediumCardiologyCardiorenal risk reduction in type 2 diabetesca-mccqe1ca-rcpsc-im
A 70-year-old man with a history of heart failure with reduced EF and CKD stage 3 has type 2 diabetes with A1c 7.3% on metformin alone. He is already on ACE inhibitor and beta-blocker. According to Canadian cardiovascular-diabetes guidance, which antihyperglycaemic agent would provide the greatest additional cardiovascular and renal benefit?